"Protein Kinase Inhibitors/metabolism"[MeSH] - Search Results

Year	Number of Results
2003	1
2004	26
2005	70
2006	92
2007	121
2008	153
2009	194
2010	263
2011	261
2012	255
2013	294
2014	334
2015	346
2016	296
2017	374
2018	342
2019	389
2020	389
2021	279
2022	92
2023	48
2024	12

1

Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes.

Roskoski R Jr. Roskoski R Jr. Pharmacol Res. 2016 Jan;103:26-48. doi: 10.1016/j.phrs.2015.10.021. Epub 2015 Oct 31. Pharmacol Res. 2016. PMID: 26529477 Review.

2

Research progress of mTOR inhibitors.

Chen Y, Zhou X. Chen Y, et al. Eur J Med Chem. 2020 Dec 15;208:112820. doi: 10.1016/j.ejmech.2020.112820. Epub 2020 Sep 13. Eur J Med Chem. 2020. PMID: 32966896 Review.

3

Brain-restricted mTOR inhibition with binary pharmacology.

Zhang Z, Fan Q, Luo X, Lou K, Weiss WA, Shokat KM. Zhang Z, et al. Nature. 2022 Sep;609(7928):822-828. doi: 10.1038/s41586-022-05213-y. Epub 2022 Sep 14. Nature. 2022. PMID: 36104566 Free PMC article.

4

Bruton's Tyrosine Kinase Inhibition in Multiple Sclerosis.

Schneider R, Oh J. Schneider R, et al. Curr Neurol Neurosci Rep. 2022 Nov;22(11):721-734. doi: 10.1007/s11910-022-01229-z. Epub 2022 Oct 27. Curr Neurol Neurosci Rep. 2022. PMID: 36301434 Free PMC article. Review.

5

Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review.

Appeldoorn TYJ, Munnink THO, Morsink LM, Hooge MNL, Touw DJ. Appeldoorn TYJ, et al. Clin Pharmacokinet. 2023 Apr;62(4):559-571. doi: 10.1007/s40262-023-01225-7. Epub 2023 Mar 31. Clin Pharmacokinet. 2023. PMID: 37000342 Free PMC article.

6

Protein kinase inhibitors: contributions from structure to clinical compounds.

Johnson LN. Johnson LN. Q Rev Biophys. 2009 Feb;42(1):1-40. doi: 10.1017/S0033583508004745. Epub 2009 Mar 19. Q Rev Biophys. 2009. PMID: 19296866 Review.

7

Metabolism considerations for kinase inhibitors in cancer treatment.

Duckett DR, Cameron MD. Duckett DR, et al. Expert Opin Drug Metab Toxicol. 2010 Oct;6(10):1175-93. doi: 10.1517/17425255.2010.506873. Expert Opin Drug Metab Toxicol. 2010. PMID: 20684746 Free PMC article. Review.

8

Considering the Oral Bioavailability of Protein Kinase Inhibitors: Essential in Assessing the Extent of Drug-Drug Interaction and Improving Clinical Practice.

Le Louedec F, Puisset F, Chatelut E, Tod M. Le Louedec F, et al. Clin Pharmacokinet. 2023 Jan;62(1):55-66. doi: 10.1007/s40262-022-01200-8. Epub 2023 Jan 11. Clin Pharmacokinet. 2023. PMID: 36631685 Review.

9

Recent advances in understanding the hepatotoxicity associated with protein kinase inhibitors.

Shi Q, Yang X, Ren L, Mattes WB. Shi Q, et al. Expert Opin Drug Metab Toxicol. 2020 Mar;16(3):217-226. doi: 10.1080/17425255.2020.1727886. Epub 2020 Feb 12. Expert Opin Drug Metab Toxicol. 2020. PMID: 32050817 Review.

10

Irreversible protein kinase inhibitors: balancing the benefits and risks.

Barf T, Kaptein A. Barf T, et al. J Med Chem. 2012 Jul 26;55(14):6243-62. doi: 10.1021/jm3003203. Epub 2012 Jun 8. J Med Chem. 2012. PMID: 22621397 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

3,954 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

3,954 results

Results by year